GlobeNewswire Inc.··NaCartesian Therapeutics Lands $150M Non-Dilutive Funding Ahead of Key Phase 3 Data
Cartesian Therapeutics secures $150M non-dilutive financing from K2 HealthVentures, extending runway to 2028 while awaiting Phase 3 trial results in early 2027.
RNACautoimmune diseasescell therapy